In the span of 48 hours, American influenza medicine took two steps that had been decades in development. On June 17, 2026, the FDA approved the first generic version of baloxavir marboxil — bringing a single-dose flu treatment to a price point accessible to millions more Americans. On June 18, the FDA's Vaccines and Related Biological Products Advisory Committee convened for the first-ever advisory vote on an mRNA influenza vaccine.
The timing is not coincidental — both were timed for the 2026–27 flu season. And both are arriving against a backdrop that makes them urgently necessary.
